TCT-432 FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-up Clinical Outcomes Final Results
Bouras G, Abizaid A, Lutz M, Carrie D, Weber-Albers J, Dudek D, Gambone L, Anderson J, Lansky A. TCT-432 FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-up Clinical Outcomes Final Results. Journal Of The American College Of Cardiology 2018, 72: b174. DOI: 10.1016/j.jacc.2018.08.1597.Peer-Reviewed Original ResearchFollow